Group B Streptococcus Vaccine: State of the Art

This article, published in Therapeutic Advances in Vaccines, provides an overview of the burden of invasive disease caused by group B Streptococcus (GBS) in infants and adults, and highlights strategies for the development of an effective vaccine against GBS infections. Despite significant advances in the prevention and treatment of neonatal disease, sepsis and meningitis caused by GBS still represent a significant public health concern globally. The authors argue that additional prevention and therapeutic strategies against infection are needed, and the availability of an effective vaccine against GBS would provide an effective means of controlling the disease.

Author: Nuccitelli A, Rinaudo CD, Maione D

Published: 2015

» Visit web page (English)

(Located at

Citation: Nuccitelli A, Rinaudo CD, Maione D. Group B Streptococcus Vaccine: State of the Art. Therapeutic Advances in Vaccine. 2015;3(3):76-90. 

Resource types: Peer-reviewed journal

Diseases/vaccines: Group B Streptococcus (GBS)

Topics: Disease burden and surveillance, Disease/vaccine specific information

Regions: Global